X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs WYETH LTD - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER WYETH LTD PFIZER/
WYETH LTD
 
P/E (TTM) x 36.1 27.7 130.2% View Chart
P/BV x 5.3 5.3 99.2% View Chart
Dividend Yield % 0.6 1.3 50.4%  

Financials

 PFIZER   WYETH LTD
EQUITY SHARE DATA
    PFIZER
Mar-18
WYETH LTD
Mar-13
PFIZER/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs2,3651,044 226.4%   
Low Rs1,625818 198.7%   
Sales per share (Unadj.) Rs430.3298.6 144.1%  
Earnings per share (Unadj.) Rs78.757.2 137.5%  
Cash flow per share (Unadj.) Rs93.258.4 159.5%  
Dividends per share (Unadj.) Rs20.0017.00 117.6%  
Dividend yield (eoy) %1.01.8 54.9%  
Book value per share (Unadj.) Rs586.5249.5 235.1%  
Shares outstanding (eoy) m45.7522.72 201.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.63.1 148.7%   
Avg P/E ratio x25.316.3 155.8%  
P/CF ratio (eoy) x21.415.9 134.3%  
Price / Book Value ratio x3.43.7 91.1%  
Dividend payout %25.429.7 85.6%   
Avg Mkt Cap Rs m91,27121,157 431.4%   
No. of employees `0002.60.5 534.6%   
Total wages/salary Rs m3,143400 785.7%   
Avg. sales/employee Rs Th7,484.813,787.4 54.3%   
Avg. wages/employee Rs Th1,195.0813.0 147.0%   
Avg. net profit/employee Rs Th1,369.12,643.3 51.8%   
INCOME DATA
Net Sales Rs m19,6856,783 290.2%  
Other income Rs m1,143353 324.1%   
Total revenues Rs m20,8287,136 291.9%   
Gross profit Rs m5,0031,617 309.3%  
Depreciation Rs m66327 2,490.6%   
Interest Rs m46 76.4%   
Profit before tax Rs m5,4791,938 282.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,878632 297.1%   
Profit after tax Rs m3,6011,301 276.9%  
Gross profit margin %25.423.8 106.6%  
Effective tax rate %34.332.6 105.1%   
Net profit margin %18.319.2 95.4%  
BALANCE SHEET DATA
Current assets Rs m24,1676,984 346.0%   
Current liabilities Rs m9,5442,056 464.2%   
Net working cap to sales %74.372.6 102.3%  
Current ratio x2.53.4 74.5%  
Inventory Days Days5599 55.5%  
Debtors Days Days2924 119.9%  
Net fixed assets Rs m9,514244 3,894.2%   
Share capital Rs m458227 201.4%   
"Free" reserves Rs m26,3755,441 484.8%   
Net worth Rs m26,8325,668 473.4%   
Long term debt Rs m2525 100.0%   
Total assets Rs m36,9007,901 467.0%  
Interest coverage x1,305.5353.3 369.5%   
Debt to equity ratio x00 21.1%  
Sales to assets ratio x0.50.9 62.1%   
Return on assets %9.816.5 59.1%  
Return on equity %13.422.9 58.5%  
Return on capital %20.434.0 60.0%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m2215 147.4%   
Fx outflow Rs m1,4892,677 55.6%   
Net fx Rs m-1,466-2,662 55.1%   
CASH FLOW
From Operations Rs m3,318923 359.4%  
From Investments Rs m-2,383317 -752.0%  
From Financial Activity Rs m-1,104-481 229.4%  
Net Cashflow Rs m-169759 -22.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 51.1 125.0%  
Indian inst/Mut Fund % 7.5 11.3 66.4%  
FIIs % 4.9 7.2 68.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 30.4 78.0%  
Shareholders   85,207 21,978 387.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY18); Net Profit Up 53.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, PFIZER has posted a net profit of Rs 1 bn (up 53.6% YoY). Sales on the other hand came in at Rs 5 bn (up 14.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 19, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS